AnaptysBio Spin-Off Spurs 14.8% Rally as Jemperli Royalty Model Debuts
AnaptysBio completed a spin-off of First Tracks Biotherapeutics and pivoted to royalty management of Jemperli with GSK and imsidolimab with Vanda. A favorable court ruling preserving Jemperli royalty rates triggered a 14.8% stock jump ahead of predicted Q2 EPS loss of $0.72 on roughly $20 million revenue.
1. Business Model Shift
AnaptysBio completed the spin-off of First Tracks Biotherapeutics and is now focused on managing royalties from its licensed assets, including Jemperli partnered with GSK and imsidolimab with Vanda Pharmaceuticals.
2. Q2 Earnings Forecast
Analysts forecast a second-quarter EPS loss of roughly $0.72 on approximately $20 million in revenue, with alternative estimates suggesting a loss near $0.77 on $27.5 million, representing significant year-over-year improvement.
3. Court Ruling Boosts Stock
A court decision dismissed a GSK subsidiary’s contract claim, safeguarding existing royalty rates for Jemperli, which catalyzed a single-session stock increase of 14.8%.
4. Financial Health Metrics
Despite a negative trailing P/E ratio of -139.9, the company maintains a strong current ratio of 9.07, indicating ample liquidity to meet near-term obligations.